Back
Eli Lilly Delays Oral Weight-Loss Pill, Targets Q2 Approval
Back
Stock News
Themes
Eli Lilly Delays Oral Weight-Loss Pill, Targets Q2 Approval
Donald Trump
Eli Lilly Delays Oral Weight-Loss Pill, Targets Q2 Approval
Edgen Stock
·
Jan 13 2026, 03:07
Share to
Share to
Copy link
LLY
+3.89%
source:
[1] Eli Lilly (LLY.US) expects its weight loss drug to be approved as early as the second quarter
Recommend
Johnson Holdings Halts Trading on Hong Kong Exchange
Jan 22 2026, 06:42
Innoscience Chairman Locks Up 155M Shares, Stock Climbs 7%
Jan 22 2026, 06:42
NVE Revenue Climbs 23% on Strong R&D Contracts
Jan 22 2026, 06:41
Edgen Stock·Jan 13 2026, 03:07
